

=> d ibib abs ind 18 2-2

L8 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2002:276421 HCAPLUS  
 DOCUMENT NUMBER: 136:278150  
 TITLE: **Immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins  
 INVENTOR(S): **Goldenberg, David M.**  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. 6,134,982.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002041847	A1	20020411	US 2001-921290	20010803
US 6306393	B1	20011023	US 1999-307816	19990510
PRIORITY APPLN. INFO.:			US 1998-38995	A2 19980312
			US 1999-307816	A2 19990510
			US 1997-41506P	P 19970324

AB B-cell, T-cell, myeloid-cell, mast-cell, and plasma-cell disorders are significant contributors to illness and mortality in **domestic animals**, especially in companion animals such as dogs and cats. These disorders include both autoimmune disorders and malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma, acute and chronic lymphocytic or myeloid leukemias, multiple myeloma, and mastocytomas. Antibody components that bind with B-cell or T-cell antigens or epitopes, as well as antigens or epitopes of myeloid, plasma and mast cells provide an effective means to treat these disorders in **domestic animals**. The **immunotherapy** uses naked antibodies, immunoconjugates and fusion proteins, alone or in combination with standard therapeutic regimens.

IC ICM A61K039-395  
 ICS A61K051-00

NCL 424001490

CC 15-3 (Immunochemistry)  
 Section cross-reference(s): 1, 8

ST **immunotherapy** autoimmune disease cancer antibody lymphocyte antigen; mast cell antigen antibody **immunotherapy** autoimmune disease cancer; myeloid cell antigen antibody **immunotherapy** autoimmune disease cancer

IT Antitumor agents  
 (B-cell lymphoma; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD126; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)

IT CD antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD33; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies,

- immunoconjugates and fusion proteins)
- IT CD antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(CD52; **immunotherapy** of malignant and autoimmune disorders in  
**domestic animals** using naked antibodies,  
immunoconjugates and fusion proteins)
- IT Histocompatibility antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HLA-DR; **immunotherapy** of malignant and autoimmune disorders  
in **domestic animals** using naked antibodies,  
immunoconjugates and fusion proteins)
- IT Antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HM1.24; **immunotherapy** of malignant and autoimmune disorders  
in **domestic animals** using naked antibodies,  
immunoconjugates and fusion proteins)
- IT Cell adhesion molecules  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(ICAM-1 (intercellular adhesion mol. 1); **immunotherapy** of  
malignant and autoimmune disorders in **domestic**  
**animals** using naked antibodies, immunoconjugates and fusion  
proteins)
- IT Histocompatibility antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Ia (H-2 I-region-associated); **immunotherapy** of malignant and  
autoimmune disorders in **domestic animals** using  
naked antibodies, immunoconjugates and fusion proteins)
- IT Histocompatibility antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(MHC (major histocompatibility complex), class II;  
**immunotherapy** of malignant and autoimmune disorders in  
**domestic animals** using naked antibodies,  
immunoconjugates and fusion proteins)
- IT Mucins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(MUC1; **immunotherapy** of malignant and autoimmune disorders in  
**domestic animals** using naked antibodies,  
immunoconjugates and fusion proteins)
- IT Antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(SSEA-1 (stage-specific embryonic antigen 1); **immunotherapy**  
of malignant and autoimmune disorders in **domestic**  
**animals** using naked antibodies, immunoconjugates and fusion  
proteins)
- IT Lymphoproliferative disorders  
(Waldenstrom's macroglobulinemia; **immunotherapy** of malignant  
and autoimmune disorders in **domestic animals** using  
naked antibodies, immunoconjugates and fusion proteins)
- IT Antitumor agents  
(acute lymphocytic leukemia; **immunotherapy** of malignant and  
autoimmune disorders in **domestic animals** using  
naked antibodies, immunoconjugates and fusion proteins)
- IT Antitumor agents  
(acute myelogenous leukemia; **immunotherapy** of malignant and  
autoimmune disorders in **domestic animals** using  
naked antibodies, immunoconjugates and fusion proteins)
- IT Fusion proteins (chimeric proteins)  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(antibody-containing; **immunotherapy** of malignant and autoimmune

- disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT Anemia (disease)  
(autoimmune hemolytic anemia; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT Antibodies  
RL: ARG (Analytical reagent use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(bispecific; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT Antitumor agents  
(chronic lymphocytic leukemia; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT Antitumor agents  
(chronic myelocytic leukemia; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT Dyes  
(conjugates with antibody; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT Carboranes  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(conjugates with antibody; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT Radionuclides, biological studies  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(conjugates with antibody; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT Drugs  
(immunoconjugate containing; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT Cytokines
- Toxins  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(immunoconjugate containing; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT Drug delivery systems  
(immunoconjugates, antibody-containing; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT Antitumor agents  
Autoimmune disease  
B cell (lymphocyte)  
Cat (Felis catus)  
Chemotherapy  
Diagnosis  
Dog (Canis familiaris)  
Epitopes

Horse (Equus caballus)

Immunomodulators

Immunosuppressants

**Immunotherapy**

Mast cell

Radiotherapy

T cell (lymphocyte)

(**immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)

IT Antibodies

RL: ARG (Analytical reagent use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(**immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)

IT Antigens

CD14 (antigen)

CD19 (antigen)

CD20 (antigen)

CD22 (antigen)

CD38 (antigen)

CD4 (antigen)

CD5 (antigen)

CD8 (antigen)

Haptens

Interleukin 2 receptors

Invariant chain (class II antigen)

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(**immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)

IT Antitumor agents

(lymphoma; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)

IT Mast cell

(mastocytoma, inhibitors; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)

IT Antitumor agents

(mastocytoma; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)

IT Antibodies

RL: ARG (Analytical reagent use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(monoclonal; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)

IT Antitumor agents

(multiple myeloma; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)

IT Antibodies

RL: ARG (Analytical reagent use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

- (multispecific; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT Hematopoietic precursor cell  
(myeloid; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT Antitumor agents  
(non-Hodgkin's lymphoma; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT Chemicals  
(photoactive, conjugates with antibody; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT Lymphocyte  
(plasma cell; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT Complement receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(type 2; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT 9001-99-4, RNase  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(immunoconjugate containing; **immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)
- IT 50-18-0, Cyclophosphamide 50-24-8, Prednisolone 57-22-7, Vincristine 10043-66-0D, I 131, labeled immunoconjugate, biological studies 10098-91-6D, Y 90, labeled immunoconjugate, biological studies 23214-92-8, Doxorubicin  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(**immunotherapy** of malignant and autoimmune disorders in **domestic animals** using naked antibodies, immunoconjugates and fusion proteins)